GlassScriptPhysician profile
Chisaroka Echendu
NPI 1336404748
$1,632.56
in general payments reported to CMS, 2019-2025
41 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $60.97 · 2022: $283 · 2023: $302 · 2024: $489 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,106 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,106.24 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $177.39 | 2019-2025 | Erleada, Akeega, Rybrevant |
| Incyte Corporation | $143.59 | 2022-2025 | Monjuvi, Jakafi, Pemazyre |
| Puma Biotechnology, INC. | $132.74 | 2022-2025 | Nerlynx |
| Rigel Pharmaceuticals, INC. | $80.63 | 2022-2023 | Rezlidhia, Tavalisse |
| Bayer Healthcare Pharmaceuticals INC. | $75.63 | 2019-2025 | |
| Recordati_rare_diseases_inc. | $71.31 | 2024 | Sylvant |
| Merck Sharp & Dohme LLC | $63.82 | 2022-2024 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $56.59 | 2023-2024 | |
| Immunocore Limited | $50.63 | 2025 | Kimmtrak |
| Visionrt, INC. | $45.98 | 2023 | |
| Tersera Therapeutics LLC | $42.96 | 2023-2024 | Zoladex |
| Daiichi Sankyo INC. | $38.05 | 2020-2024 | Enhertu |
| Jazz Pharmaceuticals INC. | $36.93 | 2019-2022 | |
| Olympus America INC. | $34.94 | 2020 | |
| Lilly USA, LLC | $33.38 | 2019-2024 | Verzenio, Retevmo, Jaypirca |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chisaroka Echendu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.